lisuride

Ligand id: 43

Name: lisuride

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 51.37
Molecular weight 338.21
XLogP 2.24
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Boess FG, Monsma FJ, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ. (1997)
Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.
Neuropharmacology36: 713-720. [PMID:9225298]
2. Boess FG, Monsma FJ, Meyer V, Zwingelstein C, Sleight AJ. (1997)
Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.
Mol Pharmacol52: 515-523. [PMID:9284367]
3. Boess FG, Monsma FJ, Sleight AJ. (1998)
Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor.
J Neurochem71: 2169-2177. [PMID:9798944]
4. Boess FG, Riemer C, Bos M, Bentley J, Bourson A, Sleight AJ. (1998)
The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.
Mol Pharmacol54: 577-583. [PMID:9730917]
5. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K. (2000)
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Synapse35: 144-150. [PMID:10611640]
6. Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR. (1999)
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
J Neurochem72: 2127-2134. [PMID:10217294]
7. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
J Pharmacol Exp Ther303: 791-804. [PMID:12388666]
8. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. (1993)
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Mol Pharmacol43: 320-327. [PMID:7680751]
9. Newman-Tancredi A, Conte C, Chaput C, Verriele L, Audinot-Bouchez V, Lochon S, Lavielle G, Millan MJ. (1997)
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Naunyn Schmiedebergs Arch Pharmacol355: 682-688. [PMID:9205951]
10. Newman-Tancredi A, Verriele L, Chaput C, Millan MJ. (1998)
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
Naunyn Schmiedebergs Arch Pharmacol357: 205-217. [PMID:9550290]
11. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC. (1993)
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
Proc Natl Acad Sci U S A90: 8547-8551. [PMID:8397408]
12. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. (1993)
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
J Biol Chem268: 18200-18204. [PMID:8394362]